(Q85303251)
Statements
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study (English)
R G Langley
M Abe
D R Baker
P Konno
S Haemmerle
H J Thurston
C Papavassilis
H B Richards
18 January 2013